Investigators sought to determine the use of comprehensive genome profiling in patients with advanced NSCLC related to time of diagnosis and the effect on receipt targeted treatment.
Oncology healthcare professionals have a unique opportunity to make a difference in the lives of AYA patients with cancer who struggle with disordered eating during their cancer treatment.
Invasive breast cancer incidence among US women aged 20 to 49 years increased from 2000 to 2019, data show.
Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers.
For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery.
A meta-analysis of 27 studies sought to determine which malnutrition assessment tools best predicted prognosis for patients with pancreatic cancer.
Most women with breast cancer do not talk with clinicians about sexual dysfunction that occurs during or after cancer treatment, a survey suggests.
Belantamab mafodotin plus bortezomib and dexamethasone could be a new standard of care for second-line or later treatment of relapsed or refractory multiple myeloma, according to researchers.
Higher plant-based diet index linked to better scores for sexual function, urinary irritation/obstruction, urinary incontinence, hormonal/vitality.
Researchers sought to confirm the effectiveness of a novel tool designed to assist patients with MM in assessing their preferences regarding treatment.
